Results for RNA ( 563 )
Total RNA was prepared from cell line WM858. WM858 is a metastatic human melanoma cell line established from a metastatic site (right axillary nodes) in a 48-year-old female with level III malignant, superficial spreading melanoma. The subject displayed polypoid VGP with a tumor thickness of 3.24mm. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses wild type PTEN, N-RAS, c-KIT, and CDK4 genes. WM858 cells match with WM873-1 and WM873-2. These cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM873-1. WM873-1 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses PTEN loss of function including hemizygous deletion, and is wild type for N-RAS, c-KIT, and CDK4 genes. WM873-1 cells match with WM858 and WM873-2. These cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM873-1. WM873-1 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses PTEN loss of function including hemizygous deletion, and is wild type for N-RAS, c-KIT, and CDK4 genes. WM873-1 cells match with WM858 and WM873-2. These cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM873-1. WM873-1 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line expresses PTEN loss of function including hemizygous deletion, and is wild type for N-RAS, c-KIT, and CDK4 genes. WM873-1 cells match with WM858 and WM873-2. These cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM873-2. WM873-2 is a metastatic human melanoma cell line that displays a flat mesenchymal morphology. This cell line expresses PTEN loss of function including hemizygous deletion. WM873-2 cells match with WM858 and WM873-1. These cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM873-2. WM873-2 is a metastatic human melanoma cell line that displays a flat mesenchymal morphology. This cell line expresses PTEN loss of function including hemizygous deletion. WM873-2 cells match with WM858 and WM873-1. These cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM873-2. WM873-2 is a metastatic human melanoma cell line that displays a flat mesenchymal morphology. This cell line expresses PTEN loss of function including hemizygous deletion. WM873-2 cells match with WM858 and WM873-1. These cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM88. WM88 is a tumorigenic primary melanoma cell line with competence for metastasis. These cells display melanocytic morphology in culture. This cell line was established from a metastatic site in a male patient with level III superficial spreading melanoma with tumor thickness of 0.92. This cell line contains the V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation occurs within the activation segment of the kinase domain and causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. The cells are wild type for PTEN, N-ras, c-KIT and CDK4. WM88 cells produce xenograft tumors when injected into immunocompromised mice.
Total RNA was prepared from cell line WM88. WM88 is a tumorigenic primary melanoma cell line with competence for metastasis. These cells display melanocytic morphology in culture. This cell line was established from a metastatic site in a male patient with level III superficial spreading melanoma with tumor thickness of 0.92. This cell line contains the V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation occurs within the activation segment of the kinase domain and causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. The cells are wild type for PTEN, N-ras, c-KIT and CDK4. WM88 cells produce xenograft tumors when injected into immunocompromised mice.